Nanoviricides Inc (NNVC) |
|
4.65 -1 (-17.7%)
|
03-05 08:38 |
|
Open: |
5.4 |
Pre. Close: |
5.65 |
|
High:
|
5.47 |
Low:
|
4.46 |
|
Volume:
|
1,430,080 |
Market Cap:
|
50M |
|
|
|
|
NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 17 full-time employees. The firm is a development-stage company with several drugs in various stages of development. The firm focuses on its research and clinical programs on specific anti-viral therapeutics. The firm is engaged in the application of nanomedicine technologies to the issues of viral diseases. The firm's nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.476 - 5.506 |
5.506 - 5.53 |
|
Low:
|
4.399 - 4.43 |
4.43 - 4.456 |
|
Close:
|
4.601 - 4.651 |
4.651 - 4.692 |
|
Technical analysis |
as of: 2021-03-05 8:14:08 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 7.95 One year: 10.17 |
| Support: |
Support1: 3.73 Support2: 3.10 |
| Resistance: |
Resistance1: 6.81 Resistance2: 8.71 |
| Pivot: |
4.91 |
| Moving Average: |
MA(5): 5.07  MA(20): 4.92
MA(100): 3.90 MA(250): 5.26 |
| MACD: |
MACD(12,26): 0.23 Signal(9): 0.23 |
| Stochastic oscillator: |
%K(14,3): 36.91 %D(3): 34.94 |
| RSI: |
RSI(14): 49.82 |
| 52-week: |
High: 12.20 Low: 2.85 Change(%): -58.4 |
| Average Vol(K): |
3-Month: 260792 10-Days: 1374332 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.NNVC has closed above bottom band by 40.1%. Bollinger Bands are 187.9% wider than normal. The large width of the bands suggest high volatility as compared to NNVC's normal range. The bands have been in this wide range for 28 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 04 Mar 2021
Should You Sell NanoViricides Inc (NNVC) Stock Thursday Morning? - InvestorsObserver
Wed, 03 Mar 2021
NNVC Stock Price Increased 57.58%: Why It Happened - Pulse 2.0
Tue, 02 Mar 2021
Nanoviricides shares are trading higher after the company reported on the - Benzinga
Tue, 02 Mar 2021
45 Stocks Moving In Tuesday's Mid-Day Session Benzinga - Benzinga
Tue, 02 Mar 2021
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application - Yahoo Finance
Thu, 18 Feb 2021
We're Hopeful That NanoViricides (NYSEMKT:NNVC) Will Use Its Cash Wisely - Yahoo Finance
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
11 |
| Shares Float (M) |
6 |
|
% Held by Insiders
|
14.97 |
|
% Held by Institutions
|
19.66 |
|
Shares Short (K)
|
634 |
|
Shares Short P. Month (K)
|
689 |
Stock Financials |
|
EPS
|
-3.106 |
|
EPS Est This Year
|
-0.200 |
|
EPS Est Next Year
|
0.040 |
|
Book Value (p.s.)
|
1.870 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-32.6 |
|
Return on Equity (ttm)
|
-102.0 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.716 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-7 |
|
Levered Free Cash Flow (M)
|
-4 |
Stock Valuations |
|
PE Ratio
|
-1.50 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.49 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-7.31 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
